Nath Bio-Genes

how big is Nath Bio-Genes?

As of March 2024, Nath Bio-Genes (India) Ltd has a market capitalization of 368.11 Cr, with net sales of 364.91 Cr and a net profit of 38.59 Cr over the latest four quarters. Shareholder's funds are valued at 609.92 Cr, and total assets amount to 880.23 Cr.

Market Cap: Nath Bio-Genes (India) Ltd has a market capitalization of 368.11 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The company reported a sum of Net Sales of 364.91 Cr and a sum of Net Profit of 38.59 Cr for the latest 4 quarters, which is Consolidated data.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending March 2024. Shareholder's Funds are valued at 609.92 Cr, and Total Assets amount to 880.23 Cr.

What does Nath Bio-Genes do?

Nath Bio-Genes (India) Ltd is a micro-cap company in the agricultural products sector, specializing in seed production and biotechnology. As of March 2025, it reported net sales of ₹52 crore and a net profit of ₹1 crore.

Overview:<BR>Nath Bio-Genes (India) Ltd operates in the Other Agricultural Products industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1992 as 'Shivnath Farms Private Limited' and was converted into a Public Limited Company on 13 September 2000, later changing its name to Nath Bio-Genes (India) Limited on March 05, 2001. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 52 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 361 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 9.00<BR>- Industry P/E: 22<BR>- Dividend Yield: 1.04%<BR>- Debt Equity: 0.05<BR>- Return on Equity: 5.99%<BR>- Price to Book: 0.57<BR><BR>Contact Details:<BR>Address: Nath House Nath Road, P B No 318 Aurangabad, Maharashtra: 431005<BR>Tel: 91-240-2376314<BR>Email: investor@nathbiogens.com<BR>Website: http://www.nathbiogenes.com

Who are in the management team of Nath Bio-Genes?

As of March 2023, the management team of Nath Bio-Genes includes Satish Kagliwal (Managing Director), Dhiraj Rathi (Company Secretary), Jeevanlata Kagliwal, Akash Nandkishor Kagliwal (Directors), and four Independent Directors: Ashu Jain, Vadla Nagbhushanam, Madhukar Deshpande, and Hitesh Rajnikant Purohit. They oversee the company's operations and regulatory compliance.

As of March 2023, the management team of Nath Bio-Genes includes the following individuals:<BR><BR>1. Satish Kagliwal - Managing Director<BR>2. Dhiraj Rathi - Company Secretary & Compliance Officer<BR>3. Jeevanlata Kagliwal - Director<BR>4. Ashu Jain - Independent Director<BR>5. Vadla Nagbhushanam - Independent Director<BR>6. Madhukar Deshpande - Independent Director<BR>7. Hitesh Rajnikant Purohit - Independent Director<BR>8. Akash Nandkishor Kagliwal - Director<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulatory requirements.

Has Nath Bio-Genes declared dividend?

Yes, Nath Bio-Genes (India) Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of August 9, 2024. While recent price returns show volatility, the dividend contributes positively to total returns, especially over longer periods.

Nath Bio-Genes (India) Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 09 Aug 24<BR><BR>Dividend Yield: 1.04%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.86%, the dividend return was 0%, resulting in a total return of -2.86%.<BR><BR>Over the past year, the price return was 0.96%, the dividend return was 0.98%, leading to a total return of 1.94%.<BR><BR>In the 2-year period, the price return was -0.31%, the dividend return was 2.10%, which resulted in a total return of 1.79%.<BR><BR>For the 3-year period, the price return was 4.37%, the dividend return was 3.82%, yielding a total return of 8.19%.<BR><BR>In the last 4 years, the price return was -54.81%, with a dividend return of 2.09%, culminating in a total return of -52.72%.<BR><BR>Over the 5-year period, the price return was -41.79%, the dividend return was 2.52%, resulting in a total return of -39.27%.<BR><BR>Overall, Nath Bio-Genes has declared a dividend, which contributes positively to the total returns, especially in the longer term. However, the recent price returns indicate some volatility, particularly over the past few years.

Who are the peers of the Nath Bio-Genes?

Nath Bio-Genes' peers include L T Foods, KRBL, Kaveri Seed Co., and others, with varying management and growth risks. L T Foods leads in 1-year returns at 111.87%, while Nath Bio-Genes has a return of 0.99%.

Peers: The peers of Nath Bio-Genes are L T Foods, KRBL, Kaveri Seed Co., Guj. Ambuja Exp, GRM Overseas, Aelea, Indo US Bio-Tech, Tierra Agrotech, and Prime Fresh.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kaveri Seed Co. and Indo US Bio-Tech, while Good management risk is found at L T Foods. Average management risk is noted at KRBL, Guj. Ambuja Exp, Aelea, and Prime Fresh, while Nath Bio-Genes and Tierra Agrotech have Below Average management risk. Growth is Excellent at Aelea, Good at L T Foods and Indo US Bio-Tech, while Below Average growth is seen at KRBL, Kaveri Seed Co., Guj. Ambuja Exp, GRM Overseas, Nath Bio-Genes, and Tierra Agrotech. The rest have Average growth. Capital Structure is Excellent at KRBL, Kaveri Seed Co., Guj. Ambuja Exp, while Good is noted for Nath Bio-Genes and Average for L T Foods, Aelea, and Prime Fresh, with Below Average at GRM Overseas and Tierra Agrotech.<BR><BR>Return Snapshot: The peer with the highest 1-year return is L T Foods at 111.87%, while the lowest is Tierra Agrotech at -30.50%. Nath Bio-Genes has a 1-year return of 0.99%, which is significantly lower than L T Foods but higher than Tierra Agrotech. Additionally, the peers with negative six-month returns include Aelea, Indo US Bio-Tech, Tierra Agrotech, and Halder Venture.

Is Nath Bio-Genes overvalued or undervalued?

As of August 16, 2022, Nath Bio-Genes is considered very attractive and undervalued with a PE ratio of 9.43, significantly lower than its peers, while Kaveri Seed Co. is seen as expensive at a PE of 26.14, and despite its recent stock performance lagging behind the Sensex, its PEG ratio of 0.00 highlights strong growth potential.

As of 16 August 2022, the valuation grade for Nath Bio-Genes moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.43, a price to book value of 0.56, and an EV to EBITDA of 7.98. These ratios suggest that Nath Bio-Genes is trading at a significant discount compared to its peers.<BR><BR>In comparison to its industry, Kaveri Seed Co. is deemed expensive with a PE ratio of 26.14, while MANGALAM SEEDS is classified as very attractive with a PE ratio of 19.17. The PEG ratio for Nath Bio-Genes stands at 0.00, further emphasizing its undervaluation relative to growth expectations. Notably, the company's recent stock performance has lagged behind the Sensex, particularly over the 3-year and 5-year periods, which may reflect market sentiment rather than its fundamental value.

What is the technical trend for Nath Bio-Genes?

As of May 27, 2025, Nath Bio-Genes shows a mildly bearish trend primarily due to daily moving averages, despite some conflicting signals from weekly and monthly indicators.

As of 27 May 2025, the technical trend for Nath Bio-Genes has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and Bollinger Bands show mild bullishness, contrasting with the monthly bearish signals from both. The KST is bullish on the weekly but bearish monthly, and the Dow Theory reflects a mildly bullish trend on the weekly with no trend monthly. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly bearish indicators.

Who are the top shareholders of the Nath Bio-Genes?

The top shareholders of Nath Bio-Genes include Ashu Farms LLP with 13.68% and Mayo Farms LLP with 5.72%. Individual investors hold 31.94%, while mutual funds have 3.89% and foreign institutional investors hold 0.21%.

The top shareholders of Nath Bio-Genes include Ashu Farms LLP, which holds the highest promoter stake at 13.68%. Additionally, Mayo Farms LLP is the largest public shareholder with a holding of 5.72%. The company also has significant individual investor holdings, accounting for 31.94%. In terms of institutional investment, mutual funds hold 3.89% across nine schemes, while foreign institutional investors (FIIs) have a minor stake of 0.21% through four FIIs. It's worth noting that there is a pledged promoter holding of 16.3764%.

When is the next results date for Nath Bio-Genes?

The next results date for Nath Bio-Genes is 13 November 2025.

The next results date for Nath Bio-Genes is scheduled for 13 November 2025.

How has been the historical performance of Nath Bio-Genes?

Nath Bio-Genes has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from 278.36 crore in March 2022 to 364.91 crore in March 2025, and profit before tax improving from a loss of 63.43 crore to a profit of 40.04 crore in the same period. The company has demonstrated resilience, with positive earnings per share rising from -35.46 to 20.32.

Answer:<BR>The historical performance of Nath Bio-Genes shows a consistent growth trend in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Nath Bio-Genes has demonstrated a steady increase in net sales, rising from 278.36 crore in March 2022 to 364.91 crore in March 2025. Total operating income followed the same upward trajectory, reaching 364.91 crore in March 2025. The company's total expenditure, excluding depreciation, also increased, amounting to 315.11 crore in March 2025, up from 241.18 crore in March 2022. Operating profit, excluding other income, remained relatively stable, with a slight decrease to 49.80 crore in March 2025 from 49.86 crore in March 2024, while the overall operating profit (PBDIT) increased to 54.35 crore in March 2025. Profit before tax improved significantly from a loss of 63.43 crore in March 2022 to a profit of 40.04 crore in March 2025. Profit after tax also saw a positive trend, moving from a loss of 67.39 crore in March 2022 to a profit of 38.06 crore in March 2025. The earnings per share (EPS) reflected this growth, with values increasing from -35.46 in March 2022 to 20.32 in March 2025. Cash flow from operating activities was 17.00 crore in March 2025, down from 74.00 crore in March 2024, but the net cash inflow remained positive at 11.00 crore in March 2025, indicating a healthy liquidity position. Overall, Nath Bio-Genes has shown resilience and growth in its financial performance over the years.

Are Nath Bio-Genes (India) Ltd latest results good or bad?

Nath Bio-Genes (India) Ltd's latest results show strong revenue growth of 78.90% to ₹65.96 crores, but net profit has declined by 39.62% to ₹1.60 crores, indicating significant operational challenges and declining investor confidence. Overall, the financial outlook appears negative due to falling profitability and margins.

The latest results for Nath Bio-Genes (India) Ltd present a mixed picture, but overall, they lean towards the negative side. While the company reported a significant increase in revenue, with net sales rising by 78.90% year-on-year to ₹65.96 crores, the net profit has sharply declined by 39.62% year-on-year to just ₹1.60 crores. This indicates that despite strong sales growth, the company's profitability is under severe pressure.<BR><BR>One of the most concerning aspects is the operating margin, which has collapsed from 21.81% in the previous year to just 5.43%. This dramatic decline suggests that the company is facing significant operational challenges, likely due to rising input costs and competitive pressures. Additionally, interest costs have surged to their highest level, consuming a substantial portion of the operating profit, which further strains profitability.<BR><BR>Investor confidence appears to be waning, as evidenced by the drastic reduction in mutual fund holdings from 4.37% to a mere 0.01% over recent quarters. The stock has also underperformed significantly, declining 11.91% over the past year, which is notably worse than the broader market.<BR><BR>In summary, while Nath Bio-Genes has achieved impressive revenue growth, the substantial drop in net profit and operating margins, coupled with rising costs and declining investor confidence, paint a concerning picture of its financial health.

Should I buy, sell or hold Nath Bio-Genes (India) Ltd?

Why is Nath Bio-Genes (India) Ltd falling/rising?

As of 16-Mar, Nath Bio-Genes (India) Ltd's stock price has risen slightly to Rs 142.85 after three days of decline, but it remains underperforming with a 4.45% drop over the past month and trading below key moving averages. The decrease in delivery volume by 40.44% suggests waning investor interest, contributing to ongoing performance challenges.

As of 16-Mar, Nath Bio-Genes (India) Ltd is experiencing a slight rise in its stock price, currently at Rs 142.85, with a change of 0.25 (0.18%) upwards. This increase comes after three consecutive days of decline, indicating a potential trend reversal. However, despite this recent uptick, the stock has been underperforming over various time frames. For instance, it has fallen by 4.45% over the past month and 8.05% year-to-date, while also being 4.8% away from its 52-week low of Rs 136. <BR><BR>Additionally, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 40.44% compared to the 5-day average. This decrease in trading activity could indicate waning interest among investors, which may contribute to the stock's overall performance challenges. <BR><BR>In summary, while there is a minor rise in the stock price today, the broader context shows significant challenges, including underperformance against benchmarks and declining investor engagement.

Which are the latest news on Nath Bio-Genes?

Which are the latest news on Nath Bio-Genes?

Which are the latest news on Nath Bio-Genes?